InVivo Therapeutics chief science officer Dr. Edward Wirth resigned his position after less than a year on the executive team.
InVivo Therapeutics CSO steps down before 1-year anniversary
InVivo Therapeutics (OTC:NVIV) chief science officer Dr. Edward Wirth resigned his post, effective Sept. 21, after just 11 months with the company.
The Cambridge, Mass.-based device maker appointed Wirth to the CSO role in October 2011, poising him to lead InVivo's efforts to win FDA approval for human trials of its biodegradable spinal cord scaffold. There was no reason given for his departure.